Nanobiotix (Euronext: NANO), a nanomedicine company with a focus on oncology, has launched a new subsidiary.
The French firm’s Curadigm unit is aiming to redefine the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry.
This subsidiary is expected to open up new growth pathways beyond oncology, built on the success and know-how that Nanobiotix has gained through the development of NBTXR3, a technology that aims to expand radiotherapy benefits for cancer patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze